

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED

阿里健康信息技術有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 00241)

**CHANGE OF EXECUTIVE DIRECTOR AND
CHIEF FINANCIAL OFFICER**

The board (the “**Board**”) of directors (the “**Directors**”) of Alibaba Health Information Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that, with effect from close of business on May 15, 2026:

- (i) Ms. Sheng Mengyue (“**Ms. Sheng**”) has been appointed as an executive Director and chief financial officer; and
- (ii) Mr. Tu Yanwu (“**Mr. Tu**”) has tendered his resignation as an executive Director and chief financial officer.

APPOINTMENT OF EXECUTIVE DIRECTOR AND CHIEF FINANCIAL OFFICER

The Board is pleased to announce that Ms. Sheng has been appointed as an executive Director and chief financial officer of the Company with effect from close of business on May 15, 2026.

Ms. Sheng, aged 44, joined Alibaba Group Holding Limited (“**Alibaba Holding**”) and its subsidiaries (collectively, “**Alibaba Group**”) in December 2019. She was the finance director of Alibaba Group and the chief financial officer of a joint venture of Alibaba Group. Ms. Sheng possesses more than 20 years of experience in auditing and financial management within the consumer and e-commerce industries. Prior to joining Alibaba Group, Ms. Sheng served in senior management positions at various globally leading conglomerates and domestic corporations from March 2008 to December 2019. Ms. Sheng also served as an auditor at a Big Four accounting firm from July 2004 to March 2008.

Ms. Sheng obtained a bachelor's degree in economics (majoring in international economics and trade) from Shanghai Jiao Tong University in the PRC in July 2004, and a Sloan Masters in Leadership and Strategy from London Business School in the United Kingdom in January 2015. Ms. Sheng is a member of the Chinese Institute of Certified Public Accountants, a Certified Internal Auditor accredited by the Institute of Internal Auditors, and a member of the Hong Kong Institute of Certified Public Accountants.

Save as disclosed herein and as at the date of this announcement, Ms. Sheng (i) is not interested or deemed to be interested in any shares or underlying shares of the Company pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) does not have any relationship with any Directors, senior management, substantial shareholders or controlling shareholders of the Company; and (iii) does not hold any directorship in any other Hong Kong or overseas listed public companies in the last three years preceding the date of this announcement, or any other position within the Company or other members of the Group.

Ms. Sheng has entered into an appointment letter as an executive Director with the Company for a term of one year commencing from May 15, 2026, which is renewable for a one-year period upon expiry of each term. She is subject to retirement by rotation and re-election at the annual general meetings of the Company in accordance with the provisions of the bye-laws of the Company and the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**"). There is no separate service contract in relation to Ms. Sheng's appointment as the chief financial officer of the Company.

Pursuant to the appointment letter between Ms. Sheng and the Company, Ms. Sheng will not receive any fees from the Company for her positions as executive Director and chief financial officer of the Company. The remuneration for Ms. Sheng's position as an executive Director, the chief financial officer of the Company and any other positions (if any) will be determined by the Company based on the recommendation from the remuneration committee of the Company (if appropriate) with reference to the Company's remuneration policy and taken into account, among other factors, her qualification and experience, responsibilities undertaken, contribution to the Company and the prevailing market level of remuneration of similar positions.

Save as disclosed herein, Ms. Sheng has confirmed that there is no other information required to be disclosed in accordance with Rule 13.51(2)(h) to (v) of the Listing Rules and there is no other matter relating to her appointment that needs to be brought to the attention of the shareholders of the Company.

The Board would like to congratulate Ms. Sheng on her new appointment.

RESIGNATION OF EXECUTIVE DIRECTOR AND CHIEF FINANCIAL OFFICER

The Board further announces that Mr. Tu has tendered his resignation as an executive Director and chief financial officer of the Company in order to devote more time to personal commitment and development with effect from close of business on May 15, 2026.

Mr. Tu has confirmed that he has no disagreement with the Board and there are no circumstances related to his resignation as an executive Director and chief financial officer of the Company which need to be brought to the attention of the Stock Exchange and the shareholders of the Company.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Tu for his valuable contributions during his tenure of directorship with the Company.

For and on behalf of the Board
Alibaba Health Information Technology Limited
Shen Difan
Chairman and Chief Executive Officer

Hong Kong, May 14, 2026

As at the date of this announcement, the Board comprises Mr. Shen Difan and Mr. Tu Yanwu as the executive Directors; Ms. Huang Jiaojiao and Mr. Xu Haipeng as the non-executive Directors; and Ms. Huang Yi Fei (Vanessa), Dr. Shao Rong and Ms. Wu May Yihong as the independent non-executive Directors.